医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hengrui to Collaborate With MabSpace on Novel Antibody Therapeutics

2015年05月19日 PM10:00
このエントリーをはてなブックマークに追加


 

SUZHOU, China

MabSpace Biosciences Co., Ltd. announced today that it has signed a collaborative contract with Jiangsu Hengrui Medicine Co., Ltd, one of the leading innovative pharmaceutical companies in China, to co-develop novel antibody therapeutics on two targets.

According to the agreement, MabSpace will be responsible for the discovery and selection of humanized lead antibodies, while Hengrui will get exclusive global rights on the resulting therapeutic candidates for the nominated targets, and will further develop the selected candidate molecules.

“MabSpace is honored to work with a prestigious company like Hengrui who has extensive capabilities in process development, manufacturing, clinical development and commercialization,” said Dr. Xueming Qian, Chairman and CEO of MabSpace. “MabSpace’s strength is our unique immune tolerance breaking-based antibody discovery platform technology, and our experience in generating novel therapeutic antibodies with differentiated profile and global IP.”

“MabSpace’s integrated capabilities of in vitro and in vivo pharmacological profiling from target to candidate molecule selection plus extensive industrial experience of its key founder in antibody discovery give us extra confidence in a successful collaboration,” commented Dr. Lianshan Zhang, President of Global R&D at Hengrui.

About MabSpace Biosciences

MabSpace Biosciences Co., Ltd. is a biotechnology company focused on the discovery and early development of antibody based therapeutics. The key advantage of its proprietary immune tolerance breaking technology (IMTB) is the ability to obtain antibodies targeting diverse epitope space on a given target, including those epitopes with high degree of cross-species identity in amino acid. MabSpace is headquartered in Hong Kong and has an R&D subsidiary with fully-integrated in vitro and in vivo pharmacology profiling capabilities in Biobay, Suzhou Industrial Park. Visit http://www.mabspacebio.com for more information.

About Hengrui

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a fully integrated pharmaceutical company in China, with annual net sales of over US$1.2 billion and an annual rate of over 20% in the past few years. It is recognized as the top innovative home-grown drug company, with about 20 new molecular entities entering clinical trials and dozens more under pre-clinical development. Hengrui’s products and R&D span over multiple therapeutic areas, such as oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media, and anti-inflammation. Visit http://www.hrs.com.cn for further information.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150519005084/en/

CONTACT

MabSpace Biosciences
Xueming Qian, +852-31149071 (HK) or
+86-512-86861702 (China)
qianxm91377@mabspacebio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作